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A b s t r a c t :  Diversity of c~-galactose based C-linked neoglycopeptides ( lb,  2b, 3c, 4d, and 5d) has been developed 
to explore the importance of subsite-assisted carbohydrate binding interactions. Deprotected C-linked 
neoglycopeptides ( lb ,  2b, 3c, 4d, and 5d) were synthesized and tested in competitive inhibition assays using a 
model enzyme-linked lectin (e.g., Maclura pomifera). Compound 2b, with two c~-galactoside units on the side 
chain of the lysine residue of the dipeptide backbone, exhibited a remarkable effect with a 2.82-fold increase in 
its inhibitory properties (IC50 1.48 raM) in comparison to lb  (IC50 4.18 raM). © 1998 Elsevier Science Ltd. All rights 
reserved. 
Molecular interactions between cell surface carbohydrate ligands and protein receptors are responsible for 
initiating a variety of biological and pathological processes (i.e., fertilization, microbial infections, inflammations 
and tumor metastasis). 2 Due to the weak nature of individual carbohydrate-protein interactions, understanding 
of such interactions, at the molecular level, are difficult to achieve. In natural systems, these weak interactions 
are usually employed in a cooperative manner which accounts for both the specificity and strength of the 
bindings.  3 To understand the importance of cooperativity in strengthening weak carbohydrate-protein 
interactions, well defined cooperative cell surface carbohydrate synthetic ligands could be used as probes for 
studying these interactions. Such probes could also be used for mapping the specific binding sites of a given 
protein receptor and could be developed further as inhibiting agents to prevent these interactions. Several 
synthetic approaches for the presentation of cooperative carbohydrate ligands on a variety of scaffolds have been 
developed and have exhibited similar or. stronger bindings to the natural systems.4, 5 In a few cases, structural 
information on the complimentary binding site of a protein receptor has been obtained by using well defined 
neoglycoconjugates. 6 
To obtain molecular level understanding of carbohydrate-protein interactions, much emphasis in the past 
few years has been paid to the synthesis of small molecules as analogs of cell surface carbohydrate ligands. 7 
With a similar goal, we are developing a flexible and control-oriented model for the bivalent presentation of 
terminal/exposed C-saccharide derivatives on a peptide/pseudo-peptide template (Figure 1). 8 This model has 
been designed to allow for variation in the presentation of the saccharide derivatives. Using this model, our aim 
is to synthesize short, preferably bivalent, C-linked neoglycopeptides in a highly controlled and flexible manner, 
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Figure 1: Model for the Presentation of Terminal~Exposed Saccharides on a 
Peptide/Pseudo-peptide Template 
and to demonstrate the importance of optimization of the presentation of the saccharide derivatives. The 
peptide/pseudo-peptide portion of the C-linked neoglycopeptides may assist in secondary interactions with 
adjacent amino acid residues of protein receptors. The model shown in Figure 1 could be developed using 
solution phase synthesis of the building blocks, followed by building block assembly on solid phase. 9 As an 
alternative to the solid phase building block assembly approach, coupling of the C-glycoside derivative to resin- 
bound peptides/pseudo-peptides could also be utilized. 10 Initial studies in our group are focused on the bivalent 
presentation of saccharide derivatives and the examination of the effect of variable presentation in a model 
enzyme-linked lectin based competitive inhibition assay, using the plant lectin Maclura pomifera. 11 
For the synthesis of C-linked neoglycopeptides, c~-galactose was selected as a saccharide derivative since it 
is the terminal saccharide of several natural ligands. 12 One such example is globotriosylceramide (GbOse3), 
which is responsible for the binding of Shiga and Shiga-like toxin receptors to host cells.13 As a terminal 
saccharide, c~-galactose is also shown to be present on the ovulated egg extra-cellular coat, the zona pellucida 
(ZP), and seems to be involved in recognition between mouse sperm and the zona pellucida. 14 
Unlike O-linked glycopeptides that are sensitive to acidic and basic media, C-linked neoglycopeptides are 
relatively stable and easy to synthesize. 9,15 In the past, synthesis of the fully protected derivatives of C- 
neoglycopeptides ( la -3a)  has been reported by our group. 8a Herein, we report a solution-phase synthesis of a 
few short C-neoglycopeptides (2--5) possessing variable bivalent presentation of c~-galactose derivatives. Fully 
deprotected C-Neoglycopeptides ( lb ,  2b, 3e, 4d, and 5d) were purified on a C-18 column by reverse-phase 
HPLC and characterized by MS-electrospray and NMR spectroscopy. 16 
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Figure 2." Molecular Diversity of C-Linked Neoglycopeptides (1-5) 
To explore the importance of subsite-assisted carbohydrate binding interactions, a model enzyme-linked lectin 
assay (ELLA) was examined in competitive inhibition assays using C-linked neoglycopeptides ( lb ,  2b, 3c, 4d, 
and 5d). Horseradish peroxidase-labeled plant lectin Maclura pomifera, isolated from the seeds of Osage orange 
tree, was allowed to bind to a water-soluble poly(acrylamide-co-allyl 0c-D-galactopyranoside) used as a lectin- 
specific coating ligand in microtiter plates.17 The effective inhibitory concentrations (IC5o values) were then 
measured and compared with methyl c~-D-galactopyranoside as a reference standard (ICso 2.18 mM) (Table 1). 18 
Table 1: Results from the inhibition of binding of horseradish peroxidase-labelled Maclura 
Pomifera to poly(acrylamide-co-allyl a-Galactopyranoside) by 
C-Neoglycopeptides (lb, 2b, 3e, 4d, and 5d) 
Compound (MW) IC50 (mM) 
l b  (448) 4.18 
2b (624) 1.48 
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3e (751) 4.31 
4d (1132) 2.84 
5d (1184) 1.50 
6, control (277) 2.57 
Me-ct-D-Gal (194) 2.18 
The replacement of  an O- by C-glycoside from compound 6 (IC50 2.57 raM) resulted in a marginal effect. 
However, the addition of a dipeptide lysine-glycine backbone (lb) greatly diminished the binding affinity for the 
lectin (IC50 4.18 mM). Compound 2b, with two ct-galactoside units on the side chain of the lysine residue of the 
dipeptide backbone, exhibited a most remarkable effect with a 2.82-fold increase in its inhibitory properties 
(IC50 1.48 mM). On the contrary, divalent derivative 3¢, which present the two ct-D-galactoside residues, in a 
more rigid manner showed greatly reduced inhibitory properties. Interestingly, a minor change in the peptide 
residue in C-neoglycopeptide 4d to 5 d, in which alanine was replaced by proline, resulted in an enhanced 
inhibitor~ effect by a factor of 2. To rule out the possibility of cross linking, the assay was performed in a 
concentration lower than required to observe such effects. Cooperativity, is not likely playing a role in the cases 
with high binding affinity, since the distances between the saccharide moieties in the divalent species are 
probably too close to reach two different binding sites from the same lectin. 
To summarize, solution-phase synthesis of C-neoglycopeptides for the variable presentation of c~-galactose 
derivatives has been achieved. The preliminary inhibition results strongly reflect upon the importance of the 
optimization of spacers for the presentation of saccharide derivatives. The enhanced binding affinity shown by 
compound 2b, created by attaching two ct-D-galactoside residues to the side chain of a lysine moiety, is highly 
surprising. Although the exact explanation of this effect is not clear at this stage. The results strongly suggest 
that the second unbound glycopeptide residue acts synergistically to increase the overall binding, possibly 
through subsite-assisted binding interactions. 
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